P76-1 Comparison of programmed death ligand-1 expression in NSCLC using 22C3 and SP142 antibodies in a single institute study

Abstract

The programmed death ligand-1 (PD-L1) expression is an important biomarker in the era of immunotherapy using immune checkpoint inhibitors. PD-L1 testing using the 22C3 antibody (Ab) has been the standard in determining the first-line therapy in advanced non-small cell lung cancer (NSCLC). Atezolizumab monotherapy has become a first-line treatment option based on the IMpower 110 trial result. However, there are few data on the effectiveness of PD-L1 staining using SP142 Ab.